Inhibition of nuclear factor-κB in T cells suppresses lung fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 12, 2007, Pages 1251-1260

  Fujimoto, Hajime ^a   D'Alessandro Gabazza, Corina N ^a   Palanki, Moorthy S S ^b   Erdman, Paul E ^b   Takagi, Takehiro ^a   Gabazza, Esteban C ^a   Bruno, Nelson E ^a   Yano, Yutaka ^a   Hayashi, Tatsuya ^a   Tamaki, Shigenori ^c   Sumida, Yasuhiro ^a   Adachi, Yukihiko ^a   Suzuki, Koji ^a   Taguchi, Osamu ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CELGENE CORPORATION   (United States)

^c National Hospital Organization Mie Chuo Medical Center   (Japan)

Author keywords

Fibrosis; T cells; Transcription factor

Indexed keywords

BLEOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN INHIBITOR; SP 100030; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SPECIFICITY; FEMALE; IN VIVO STUDY; LUNG FIBROSIS; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; MICE; NF-KAPPA B; ORGANIC CHEMICALS; PULMONARY FIBROSIS; T-LYMPHOCYTES;

EID: 37149042248     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200609-1288OC     Document Type: Article

References (37)

1. Canonico AE, Brigham KL. Biology of acute lung injury. In: Crystal RG, Barnes PJ, West JB,. Weibel ER, editors. The lung, 2nd ed. Philadelphia: Lippincott-Raven; 1997. pp. 2475-2498.
2. Agostini C, Siviero M, Semenzato G. Immune effector cells in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 1997;3:348-355.
3. Schrier DJ, Phan SH, McGarry BM. The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis: a biochemical evaluation. Am Rev Respir Dis 1983;127:614-617.
4. Marshall BG, Shaw RJ. T cells and fibrosis. Chem Immunol 2000;78:148-158.
5. Riches DWH, Worthen GS, Augustin A, Lapadat R, Chan ED. Inflammation in the pathogenesis of interstitial lung disease. In: Schwarz MI, King TE, editors. Interstitial lung disease, 4th ed. London: BC Decker; 2003. pp.187-220.
6. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
7. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82:434-448.
8. Eng E, Ballermann BJ. Diminished NF-kappaB: activation and PDGF-B expression in glomerular endothelial cells subjected to chronic shear stress. Microvasc Res 2003;65:137-144.
9. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappaB as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271-2277.
10. Huang TJ, Adcock IM, Chung KF. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br J Pharmacol 2001;134:1029-1036.
11. Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, Boyle D, Manning AM, Firestein GS. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000;165:1652-1658.
12. Manning AM, Rao A. Agents targeting transcription factors. In: Gallin JI, Snyderman R, editors. Inflammation: basic principles and clinical correlates, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 1999. pp. 1159-1176.
13. Palanki MS. Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 2002;9:219-227.
14. Takagi T, Gabazza EC, Fujimoto H, Maruyama T, Nishii Y, Nakahara H, D'Alessandro-Gabazza CN, Kobayashi H, Taguchi O. Role of NF-kappaB p50 in bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 2003;173:330.
15. Fujimoto H, Gabazza EC, Takagi T, Maruyama T, Nishii Y, Nakahara H, D'Alessandro-Gabazza CN, Kobayashi H, Taguchi O. Bleomycin-induced pulmonary fibrosis in CD4- and CD8-deficient mice. Am J Respir Crit Care Med 2003;173:230.
16. Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, Ido M, Shimizu T, Nakagi T, Kobayashi T. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003;167:1416-1426.
17. Caamano J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002:15;414-429.
18. + T lymphocytes. Science 1992;256:1452-1456.
19. Tong X, Yin L, Washington R, Rosenberg DW, Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem 2004;265:171-183.
20. Bi K, Tanaka Y, Coudronniere N, Sugie K, Hong S, van Stipdonk MJ, Altama A. Antigen-induced translocation of PKC-theta to membrane rafts is required for T cell activation. Nat Immunol 2001;2:556-563.
21. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-594.
22. Suzuki K, Gabazza EC, Hayashi T, Kamada H, Adachi Y, Taguchi O. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004;32:S262-S265.
23. Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J 2003;44:33s-35s.
24. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998;53:601-612.
25. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
26. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004;382:393-409.
27. Moscat J, Diaz-Meco MT, Rennert P. NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 2003;4:31-36.
28. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol 2002;20:761-794.
29. Manicassamy S, Gupta S, Sun Z. Selective function of PKC-theta in T cells. Cell Mol Immunol 2006;3:263-270.
30. Keane MP, Belperio JA, Strieter RM. Cytokine biology and the pathogenesis of interstitial lung disease. In: Schwarz MI, King TE, editors. Interstitial lung disease. Hamilton, ON, Canada: BC Decker; 2003. pp. 245-275.
31. Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep 2005;7:99-105.
32. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148-157.
33. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
34. Monaco C, Andreakos E, Young S, Feldmann M, Paleolog E. T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol 2002;71:659-668.
35. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, et al. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2006;173:1016-1022.
36. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-1482.
37. + T lymphocytes. J Leukoc Biol 1993;54:414-422.